Furthermore, co-targeting of PAD2 and AR with the small molecule inhibitors Cl-amidine (PAD enzyme inhibitor) and enzalutamide (AR signalling inhibitor) was shown to have a synergistic effect on reducing tumour growth, as compared to the treatment of either compound alone in a prostate cancer mouse model [82]. Here, AR is linked to prostate cancer.